Pyuria Associated Pyocolpos in the Neonates with Rare manifestations of Distal Vaginal Obstruction: Clinical, and Biomarkers Profiles in the Management Strategies

Author
Manal Mohammed Kadhim
Assistant Professor of Medical Microbiology
Department of Medical Microbiology, College of Medicine, University of Al-Qadisiyah
Email: manal.kadhim@qu.edu.iq

ABSTRACT
Background: The diagnosis of distal vaginal atresia is rare in the neonate unless the hydromucocolpos was developed. Pyuria and pyometrocolpos may complicate hydromucocolpos, it may present with severe obstructive uropathy and septicemia.
Aim: to evaluate the role of combinations of clinical, microbial and immunological parameters in enhancing and to discuss the management strategies.
Patients and Methods: Twenty-eight patients presented to the pediatrics surgery ward with clinical signs of congenital distal vaginal obstruction were prospectively studied and compared with 20 healthy control group. The clinical records and radiological findings together with laboratory findings were reviewed. Urine sample collected for enzyme-linked immunosorbent assay to measure the urinary levels of interleukin IL-4, IL-6, IL-8 and IL-10 and for macroscopically examination and culture.
Results: There was a significant rising in the immunological biomarkers in all patients group as compared with control group regardless they have associated anomalies or not, and significant correlation between IL-6, IL-8 and TNF-α rising scores with patients already presented with obstructive uropathies.
Conclusion: Pyuria associated pyocolpos in congenital vaginal obstruction is a marker for underlining urinary tract abnormalities.This should rise management strategies with early picking up the pathology promoting optimal outcome.
Keyword: Pyuria, Pyocolpos, Obstructive uropatheies, Proi-inflammatory cytokine.

INTRODUCTION
These are spectrum of female reproductive tract anomalies present with varying degrees of Müllerian fusion defects and agenesis during embryogenesis leading to a broad spectrum of phenotypes. These anomalies are generally encountered in 2- 3% of female reproductive tract abnormalities [1]. Various combinations have been described, the most common one is imperforate hymen. Incidence of isolated vaginal agenesis is 1:5000 women [2]. The diagnosis of distal vaginal atresia is rare in the neonate unless the hydromucocolpos was developed (HMC) as a result of obstruction. Rarely, in some cases, copious amounts of fluid may collect in the vagina proximal to the obstructing segment causing a mass effect with compression on the surrounding organs. Compression may cause and progress for
serious sequels if not promptly diagnosed and treated [3]. Hydromucocolpos may be diagnosed prenatally by sonography (U/S) during third-trimester. In these cases, an abdominal or pelvic mass can cause fetal abdominal distension [4]. Failure of the distal part of the vagina to develop (agenesis), transverse vaginal membrane, or an imperforate hymen are considered as the usual causes [5]. Usually these anomalies encountered in the spectrum of syndromes with associated others defect, but often remain undiagnosed for years in children with normal renal function if the radiological assessment (U/S or Intravenous urography IVU) is not performed[6-8]. The usual presentation of the neonates with distal vaginal atresia can include abdominal mass, findings of obstructive uropathy and recurrent urinary tract infections, sometimes for to late presentation with neonatal sepsis due to sever secondary infection. Pyocolpos is a result of an excess of secondary-infected cervical secretion secondary to a congenital atresia of the vaginal orifice. Children with pyometrolpos due to distal vaginal atresia may present with acute illness, with severe obstructive uropathy and septicemia [9]. However, there are very few reports of pyocolpos in children. Imaging assessments following pyuria demonstrated a high incidence of abnormalities in the renal tract, with obstructive uropathies in 1-4% [10]. Using its diversity and by qualified and sophisticated mechanisms, mucosal pathogens have own roles to access the tissues at their preferred site of infection [11]. Cytokines have a key role in the innate immunity and present the early biomarkers of the epithelial response to infection [12]. Interleukin-6 may cause fever triggering the acute-phase response, while IL-8 recruit inflammatory cells to the site of infection. Patients with urinary tract Infection (UTI) might carry high urine cytokine levels [13,14], in the murine UTI model the epithelial cells have been identified as early producers of cytokines [15]. The epithelial cytokine response of the human mucosa in situ has not been widely studied and evaluated. TNF-α behave as a pathogenic role in the maintenance and induction of glomerular barrier dysfunction [16].

Objective: Evaluation the role of combinations of clinical, microbial and immunological parameters in enhancing and to discuss the management strategies, if this information will be useful in determining the optimal intervention, follow up, outcome and to roll out infection complication of these rare congenital anomalies.

PATIENTS AND METHODS
The sample of this study was conducted in the Pediatric surgery unit at The Maternity and Child Teaching Hospital, Al-Qadisiya, from the 1st of august 2014 to the end of July 2016, all patients at the age < 30 days and presented with abdominal mass, vaginal obstruction to the outpatient clinic or to the surgical ward were investigated prospectively. The clinical course with manifestations, laboratory findings and underlying genitourinary (GU) tract anomalies were reviewed. With aseptic work up, all patients had renal function tests, urinalysis, urine culture and sensitivity (any patient showing any number of white blood cells per high-power field on a centrifuged specimen of urine microscopy was included, urine samples were taken either by catheterization or sticking of a sterile bag according to age and 5 patients were obtained from nephrostomy specimens. After informed consent and on all eligible subjects, a detailed history and examination was conducted immediately after admission. Information about age, antenatal history, birth weight, clinical examination, laboratory findings and outcome were recorded on a designed questionnaire for this study. Plain radiograph, ultrasonography (US) and computerized scan (CTS) were performed in all patients after family consent based on legal acceptance, 20 neonate were enrolled in this study as a control group during their attendance for usual routine assessment, all considered healthy and none of them carrying associated anomalies, particularly urological anomalies according their initial evaluations. The diagnosis
of pyuria was picked up according to the signs and symptoms of UTI in the newborn, fever, screaming, dysuria, frequency and a bacterial colony of at least $10^5$ organisms/ milliter in a midstream, clean voided specimen, $10^3$ or more organisms/ milliter in a catheterized urine or any growth in urine specimen aspirated through a nephrostomy tube. Urine sample form all patients and control groups were inoculated into the MacConkey and blood agar for culture and sensitivity. The enzyme-linked immunosorbent assay was used to measure the levels of urinary interleukins including IL-4, IL-6, IL-8 and IL-10. All were measured by using a commercially available ELISA kits from (Cusabio. Germany; KOMABIOTECH INC. Korea). Urine specimens were centrifuged at 1,000 x g for 10 min, and the supernatants were assayed directly or after dilution with the dilution buffer. All assays were done at least in duplicate. The detection limits of this assay were: IL-4 (1 pg/ mL), IL-6 (0.7pg/mL), IL-8 (3.5pg/mL), and IL-10 (3.9 pg/mL) respectively. By using commercially available ELISA kits from (Medgenix Diagnostics), urine TNF-α levels in normal (control) subjects and patients were measured, the detection limit was 10 pg/ml for the kit. Structural anatomy was determined by clinical examination, ultrasonography, and computerized tomography and reassessed for associated anomalies. Data were translated into a computerized database. Expert statistical advice was sought and the values are given as means and ranges, statistical analysis were done by using excel 2016 and SPSS version 22 software. Mann Whitney U test used to analyze the differences between healthy controls and patients.

RESULTS
Twenty-eight patients presented to the pediatrics surgery ward with clinical signs of congenital distal vaginal obstruction were prospectively studied. Their mean gestational age was 34-37 weeks. Prenatal, postnatal sonography with initial radiological assessment including intravenous pyelogram (IVP). The study reported associated congenital urinary tract malformations in 20 of them, figure (1). These included bilateral hydronephrosis in 50% of anomalies, right ureter duplication (15%), left ureteropelvic junction stenosis (15%), bilateral multiple cystic dysplastic kidney (10%) and right ureterocele (10%), figure (2). Evidence of obstructive uropathies encountered in 19 of patients group, 10 of them developed sever bilateral hydronephrosis, figure (3). Twenty out of 28 patient had urinary tract infections (UTI), as evidenced by pyuria and positive urine bacterial cultures with a colony count greater than $10^5$/ml, figure (4). The remarkable causative agent was Escherichia coli in 50% of these cultures, and there was significant correlation between obstructive uropathy, anomalies and urine culture among patients with pyocolpos as OR=90 and (P value < 0.0005), table (1&2).

Significant rising in the immunological biomarkers in all patients group as compared with control group regardless they have associated anomalies or not, especially IL-6, (mean 125.3pg/ml), (SE 9.13) and (P value < 0.001), IL-8 (mean 119.98pg/ml), (SE 9.8) and (P value < 0.001) and TNF-α (mean 118 pg/ml), (SE 9.6) and (P value < 0.001), To have a signaling about the predictive value of the anti-inflammatory biomarkers that may reflect any risk of renal damage associated vaginal obstruction and obstructive uropathies, we recorded statistically significant role or changing in scores for IL-4 between patients and control, (P value < 0.001), with no significant correlation in IL-10 concentration between the two groups, table (3). There was a significant elevations in symptom scores in the patients (with associated urological anomalies with culture proven urine) and IL-6 (mean143.69 pg/ml), (SE 12.7) and (P value < 0.001), IL-8 (mean133.22 pg/ml),(SE 11.86) and (P value < 0.001), and TNF-α (mean 128.44), (SE 11.42) and (P value < 0.001).But still there is a remarkable associated high level score in IL-6,IL-8,and TNF in patients with associated urological
anomalies with negative urine culture (These findings indicate that during urosepsis, the pro-inflammatory cytokine response is generated predominantly during this insult), table (4). Significant correlation between IL-6, IL-8 and TNF-α rising scores with patients already presented with obstructive uropathies, (mean 146.06 pg/ml, 136.58 pg/ml and 137.95 pg/ml) respectively (P value < 0.001), and patients without obstructive uropathies, table (5).

**Figure (1):** Pie chart show frequency of anomalies (congenital urinary tract malformations) among patients with vaginal atresia (P < 0.05).

**Figure (2):** Pie Chart show distribution the types of congenital urinary tract malformations in patients with vaginal atresia.

**Figure (3):** Pie Chart show frequency of obstructive uropathy among patients with pyocolpos (P < 0.05).
Figure (4): Pie chart show profile of urine culture among patients with pyocolpos (P< 0.05).

Table (1): Patients with pyocolpos correlated with each anomaly and urine culture.

| Anomalies                                | Patients With anomalies | Urine culture | Patients with positive urine culture |
|------------------------------------------|-------------------------|---------------|-------------------------------------|
|                                          | N           | %        |                                    | N | %       |
| Bilateral hydronephrosis                | 10          | 50       | *Pseudomonas aeruginosa*             | 4  | 20      |
| Right ureter duplication                | 3           | 15       | *Klebsiella pneumoniae*              | 2  | 10      |
| Left ureteropelvic junction stenosis   | 3           | 15       | *Proteus mirabilis*                  | 1  | 5       |
| Bilateral multiple cystic dysplastic kidney | 2          | 10       | *Escherichia coli*                   | 10 | 50      |
| Right ureterocele                        | 2           | 10       | *Staphylococcus*                     | 3  | 15      |
| Total                                    | 20          | 100      | Total                                | 20 | 100     |

Table (2): Correlation between obstructive uropathy, anomalies and urine culture among patients with pyocolpos.

| Anomalies                                | Patient with obstructive uropathy (N=19) | Patient without obstructive uropathy (N=9) | OR* (95%CI**) | P value |
|------------------------------------------|------------------------------------------|--------------------------------------------|---------------|---------|
|                                          | N (%)                                    | N (%)                                      |               |         |
| Anomalies                                | 19 (100)                                 | 1 (11)                                    | 90 (7.197 - 1125.45) | 0.0005  |
| Positive urine culture                   | 19 (100)                                 | 1(11)                                     | 90 (7.197 - 1125.45) | 0.0005  |

*OR= Odds ratio. **CI= confidence interval.
Table (3): Compared Concentration of Immunological Markers between Cases and Controls.

| Immunological markers | Case       | Control    | P value |
|-----------------------|------------|------------|---------|
| **TNF α pg/ml**       |            |            | < 0.001 |
| Range                 | 66.7-218.3 | 2.8-13.7   |         |
| Mean                  | 118        | 8.6        |         |
| SD*                   | 51.03      | 2.96       |         |
| SE**                  | 9.6        | 0.66       |         |
| N***                  | 28         | 20         |         |
| **IL-4 pg/ml**        |            |            | < 0.001 |
| Range                 | 14.9-63.5  | 0.7-13.7   |         |
| Mean                  | 39.42      | 7.21       |         |
| SD                    | 42.7       | 3.73       |         |
| SE                    | 8.7        | 0.83       |         |
| N                     | 28         | 20         |         |
| **IL-6 pg/ml**        |            |            | < 0.001 |
| Range                 | 60.7-220.7 | 0.7-12.3   |         |
| Mean                  | 125.03     | 6.545      |         |
| SD                    | 48.3       | 3.64       |         |
| SE                    | 9.13       | 0.81       |         |
| N                     | 28         | 20         |         |
| **IL-8 pg/ml**        |            |            | < 0.001 |
| Range                 | 66.4-232.8 | 2.8-18.5   |         |
| Mean                  | 119.98     | 9.365      |         |
| SD                    | 51.8       | 4.27       |         |
| SE                    | 9.8        | 0.95       |         |
| N                     | 28         | 20         |         |
| **IL-10 pg/ml**       |            |            | NS****  |
| Range                 | 11.5-25.1  | 0.7-14.6   |         |
| Mean                  | 16.59      | 7.485      |         |
| SD                    | 4.06       | 3.86       |         |
| SE                    | 0.77       | 0.863      |         |
| N                     | 28         | 20         |         |

*SD= standard deviation. **SE= standard error. *** N= Number. ****NS=non-significant.
Table (4): Compared concentration of some immunological markers between positive urine culture and negative urine culture of cases with urological anomalies.

| Immunological markers | Positive urine culture | Negative urine culture | P value |
|-----------------------|------------------------|------------------------|---------|
| **TNF α pg/ml**       |                        |                        | < 0.001 |
| Range                 | 67.5-218.3             | 66.7-197.3             |         |
| Mean                  | 128.44                 | 91.93                  |         |
| SD*                   | 51.07                  | 43.33                  |         |
| SE**                  | 11.42                  | 15.32                  |         |
| N***                  | 20                     | 8                      |         |
| **IL-4 pg/ml**        |                        |                        | NS****  |
| Range                 | 14.9-63.5              | 23.5-50.4              |         |
| Mean                  | 42.42                  | 31.93                  |         |
| SD                    | 15.64                  | 8.6                    |         |
| SE                    | 3.479                  | 3.04                   |         |
| N                     | 20                     | 8                      |         |
| **IL-6 pg/ml**        |                        |                        | < 0.001 |
| Range                 | 66.7-220.6             | 60.7-94.1              |         |
| Mean                  | 143.69                 | 78.39                  |         |
| SD                    | 56.8                   | 10.87                  |         |
| SE                    | 12.7                   | 3.843                  |         |
| N                     | 20                     | 8                      |         |
| **IL-8 pg/ml**        |                        |                        | < 0.001 |
| Range                 | 69.3-232.8             | 66.4-140.9             |         |
| Mean                  | 133.22                 | 86.875                 |         |
| SD                    | 53.03                  | 22.90                  |         |
| SE                    | 11.86                  | 8.096                  |         |
| N                     | 20                     | 8                      |         |
| **IL-10 pg/ml**       |                        |                        | NS      |
| Range                 | 11.5-25.1              | 12.5-23.2              |         |
| Mean                  | 15.89                  | 18.338                 |         |
| SD                    | 3.87                   | 4.256                  |         |
| SE                    | 0.865                  | 1.505                  |         |
| N                     | 20                     | 8                      |         |

*SD= standard deviation. **SE= standard error. *** N= Number. ****NS=non-significant.
Table (5): Compared concentration of some immunological markers between patients with and without obstructive uropathy.

| Immunological markers | Patient with obstructive uropathy | Patient without obstructive uropathy | P value |
|-----------------------|-----------------------------------|-------------------------------------|---------|
| TNF α pg/ml           |                                   |                                     | < 0.001 |
| Range                 | 70.7-218.3                        | 66.7-87.1                           |         |
| Mean                  | 137.95                            | 75.91                               |         |
| SD*                   | 50.71                             | 8.17                                |         |
| SE**                  | 11.63                             | 2.72                                |         |
| N***                  | 19                                | 9                                   |         |
| IL-4 pg/ml            |                                   |                                     | NS****  |
| Range                 | 14.9-63.5                         | 23.5-50.4                           |         |
| Mean                  | 43.19                             | 31.456                              |         |
| SD                    | 15.68                             | 8.16                                |         |
| SE                    | 3.597                             | 2.72                                |         |
| N                     | 19                                | 9                                   |         |
| IL-6 pg/ml            |                                   |                                     | < 0.001 |
| Range                 | 66.7-220.6                        | 60.7-98.6                           |         |
| Mean                  | 146.06                            | 80.63                               |         |
| SD                    | 57.33                             | 12.19                               |         |
| SE                    | 13.15                             | 4.06                                |         |
| N                     | 19                                | 9                                   |         |
| IL-8 pg/ml            |                                   |                                     | < 0.001 |
| Range                 | 70.2-232.8                        | 69.3-140.9                          |         |
| Mean                  | 136.58                            | 84.922                              |         |
| SD                    | 52.25                             | 22.21                               |         |
| SE                    | 11.99                             | 7.40                                |         |
| N                     | 19                                | 9                                   |         |
| IL-10 pg/ml           |                                   |                                     | NS      |
| Range                 | 11.5-25.1                         | 12.5-25.1                           |         |
| Mean                  | 16.06                             | 17.7                                |         |
| SD                    | 3.89                              | 4.41                                |         |
| SE                    | 0.892                             | 1.47                                |         |
| N                     | 19                                | 9                                   |         |

*SD= standard deviation. **SE= standard error. *** N= Number. ****NS=non-significant

DISCUSSION

A large series of patients with congenital uterovaginal atresia and obstruction were reported [17]. The diagnosis can be made during or between the perinatal period and adolescence. The commonest presentations were related to genitourinary obstruction (54.4%) followed equally by abdominal pain and pelviabdominal mass (45.5% for each) [18]. A fundamental component of the workup is usually approached by the physical examination but often was not adequate to establish a definitive diagnosis [19]. Pyocolpos usually presented as a mass in the lower abdomen; however, in rare cases, it was reported with infected urinary tract, acute gastrointestinal obstruction, and urinary retention [20,21].
A high incidence of urological anomalies, e.g. vesicoureteric reflux (VUR) in about 30-50% and obstructive uropathies in about 1-4% were reported in 43% of infants and children with symptomatic UTI followed by Imaging assessment [22,23]. In our series 19 cases with obstructive uropathies due to severe urethral outlet compression and bilateral VUR. Regardless that the distal vaginal atresia studied here carrying these series of uropathies, again many literates announced risk of UTI or urosepsis associated anomalies e.g. In Williams’ series [24], the UTI incidence with pelviuretericjunction (PUJ) obstruction was 45.8% and Bauer et al [25] demonstrated that the UTI is the most common presentation in children with bladder diverticula. In our series Escherichia coli presented as a causative agent in more than 50% of our culture proven urine in patients group. Despite there was a little dispute that E. coli is the most common pathogen found in pediatric age group, many epidemiological studies reported that Uropathogenic Escherichia coli (UPEC) is the most common etiological agent responsible for uncomplicated UTI [26]. Recently the serum and urine levels of pro-inflammatory cytokines became important biomarkers in the assessment of urological disorders [27]. Focusing on our results the high inflammatory biomarkers correlating with anomalies or without, with obstructive uropathies or without, proved the localizations of renal system were stained in favor of evidence for biomarkers particularly the role of IL-6, IL-8and TNF-α in such insults and pathology. Many articles highlighted e.g. the usefulness of IL-6 as an early marker for renal pathology and even anomalies, proven its implications and differences in the staining between the both disorders with and without pathology of the epithelium in the urinary tract [28,29]. This reflect the enrollment of IL-6 high scores in our patient’s series due to the anatomical defect (obstruction and compression) made the epithelial cells of renal system (bladder and kidney) producing IL-6 as a response to external stimuli [30]. It is also a product of inflammatory cells such as mononuclear phagocytes, mast cells and lymphocytes. On the other hand, IL-6 expressed in the cell of the smooth muscle, epithelial cell, endothelium and fibroblasts of the normal bladder, as well. Due to its widespread cellular sources (an inducer of activation and differentiation of B and T cells during inflammation) [31]. The highest scoring IL-6, IL-8 and TNF-α in severe obstructive uropathies and bilateral hydronephrosis in our patients group reflected the sever renal damage might happen by these anomalies with particular and clear correlation with the excretion of IL-8 (neutrophil-activation protein excreted from the renal tubules due to acute inflammatory insults) proven its role with such higher initial urine levels. many researchers reported such evidence in children with acute pyelonephritis and the significant of cytokines markers in renal disorder despite no significant differentiate between upper or lower urinary pathology or infection [32,33]. In our study the similar score might indicate the early renal insult and flare up the pictures of inflammation regardless presence of infection or not. Galanakis et al, hypothesized same pathway correlating the IL-8 and renal pathology [34]. With the same pattern TNF-α recorded itself with such high scores in our patients with obstructive, associated anomalies and culture proven urine, indicating that such pathology may potentiate the production of pro-inflammatory biomarker TNF-α by monocytes in human upon stimulation of different types of cells, including renal fibroblasts which is able to produce IL-8 in response to TNF-α [35]. Despite the known sequel and complication of UTI, our critical anomalies with such critical age group should emphasized empirical surveillance and strict follow up to pick up the early sign of renal scaring reflected by these pro-inflammatory cytokines in the urine. Other researchers declared the correlation of elevated urinary biomarkers IL-6, IL-8 and TNF-α and renal parenchymal damage rather than VUR and they can early predict this pathology [36-39]. Our records with significant finding and the correlation of IL-4 (which
considered as anti-inflammatory interleukin that exerts immunosuppressive effects on macrophages and suppresses pro-inflammatory cytokine production) between the patients and control group may reflect the fact of its contribution in pathological changes in glomerular level by stimulating collagen synthesis in human mesangial cells [40]. Many hypotheses pointed to the enrollment of IL-10 (a cytokine with anti-inflammatory and immunomodulatory functions, regulates the biology of B and T cells) in the induction of cellular and molecular pathways and their link to the progression of kidney damage [41].

Our results with such low score in patients group (slightly more than control one) may hypothesized identical report by Madsen, he submitted significantly lower levels of IL-10 in renal parenchyma and urine of animals with acute unilateral obstruction, while renal levels of IL-1β, IL-6, and TNF-α were increased to sham-operated animals (normal operated as a control) [42]. Some studies may deny such associations and their conclusions were controversial, possibly due to the small sample sizes [43]. Our results went beside many studies dealing with the pivotal role and the balance between pro- (IL-6, IL-8 and TNF-α) and anti-inflammatory cytokines (Il-4 and IL-10) which determines the inflammatory response and may be mediate the progression of renal disease [44-46].

Our small size study for both patients and control groups made some limitations. Although we think that we have submitted a promising results with such sample studied in our local community, we agreed much more remain need to be investigated and evaluated dealing with such rare congenital anomalies.

Conclusion: Focusing in our results with such critical anomalies carrying serious sequel especially due to the associated urological anomalies, accordingly we should highlight the strict assessment and follow up for those patient proposing algorithm including non-invasive clinical and para clinical methods of investigation with complete imaging work up. Pyuria associated pyocolpos in congenital vaginal obstruction is a marker for underlining urinary tract abnormalities. This should rise management strategies with early picking up the pathology promoting optimal outcome.

COMPETING INTERESTS
The author declares that they have no competing interests.

ACKNOWLEDGMENTS
The author would like to thank all the staff of the Pediatric Surgery Unit, The Maternity and Child Teaching Hospital, Al Qadisiya, for their kind assistance and for all workup they done, the laboratory staff of the Department of Medical Microbiology, College of Medicine, Al Qadisiya University for providing equipment and premises to design and submitting our study. The author read and approved the final manuscript.

REFERENCES
1. Gray SW et al. The female reproductive tract. In: Skandalakis JE, Gray SW, editors. Embryology for surgeons. Baltimore (MD): Williams & Wilkins; 1994; p.816-47.
2. Salvatore CA, Lodovicci O. Vaginal agenesis: an analysis of ninety cases. Acta Obstet Gynecol Scand 1978; 57:89-94.
3. Jones HW: Reconstruction of congenital uterovaginal anomalies. In: Rock JA, Murphy AA, Jones HW, eds. Female Reproductive Surgery. Baltimore, Md: Lippincott Williams & Wilkins; 1992; 246.
4. Banerjee AK et al. Sonographic detection of neonatal hydrometrocolpos. Br J Radiol 1992 Mar; 65(771): 268-71 [Medline].
5. David A et al. Hydrometrocolpos and polydactyly: a common neonatal presentation of Bardet-Biedl and McKusick-Kaufman syndromes.J Med Genet. 1999; 36:599–603. [PMC free article: PMC1762973] [PubMed: 10465109].
6. Riise R et al. Intra familial variation of the phenotype in Bardet-Biedl syndrome. Br J
Ophthalmol. 1997; 81:37–85. [PMC free article: PMC1 7221 98] [PubMed: 9227 203].

7. Harnett JD et al. The spectrum of renal disease in Laurence-Moon-Biedl syndrome. Eng J Med 1988; 319:615-18.

8. McCann E et al. Genitourinary malformations as a feature of the Pallister–Hall syndrome: Clinical Dysmorphology 2006; 15:75–79.

9. Imamoglu M et al: Two cases of pyometrocolpos due to distal vaginal atresia. PediatrSurgInt 2005 Mar; 21(3):217-9[Medline].

10. Dick PT, Feldman W. Routine diagnostic imaging for childhood urinary tract infections: a systematic overview. J Pediatr 1996; 128:15-22.

11. Bleves S., and G. R. Cornelis. How to survive in the host: The Yersinia lesson. Microbes Infect. 2000; 2:1451–1460.

12. Svanborg C et al. Cytokine responses during mucosal infections: role in disease pathogenesis and host defense. Curr. Opin. Microbiol.1999; 2:99–105.

13. Olszyna D et al. Sequential measurements of chemokines in urosepsis and experimental endotoxemia. J. Clin. Immunol.1999;19:399–405.

14. Otto G et al. Interleukin-6 and disease severity in patients with bacteremic and non-bacteremic febrile urinary tract infection. J. Infect. Dis.1999; 179:172–179.

15. Haraoka M et al. Neutrophil recruitment and resistance to urinary tract infection. J Infect. Dis. 1999; 180:1220–1229.

16. Suranyi MG et al. Elevated levels of tumour necrosis factor-α in the nephrotic syndrome in humans. American journal of kidney disease, 1993, 21(3):251–9.

17. Spencer R, Levy DM: Hydrometrocolpos. Ann Surg. 1962; 155:558–571.

18. Rayband C et al. Mayer-Rokitansky-Kuster-Hauser Syndrome: associated pathologies. Arch Pediatr. 2001; 8:1209-13.

19. Meyer WR et al. Combined abdominal perineal sonography to assist in diagnosis of transverse vaginal septum. Obstet Gynecol. 1995; 85:882-884.

20. Brevetti LS et al. Pyocolpos: diagnosis and treatment. J Pediatr Surg. 1997; 32:110-1.

21. Srivastava P et al. Pyocolpos with distal vaginal atresia during infancy presented with acute intestinal obstruction and acute urinary retention: report of a rare case. Internet J Surg.2009 Aug.12; 2:17.

22. Jodal U and Hansson S: Urinary tract infection. In: Pediatric Nephrology. Edited by Holliday, M.A., Barratt, T.M., and Anver, E.D., Baltimore: Williams & Wilkins, 1994; pp. 950–62

23. Downs SM. Technical report: urinary tract infections in febrile infants and young children. The Urinary Tract Subcommittee of the American Academy of Pediatrics Committee on Quality Improvement. Pediatrics 1999; 103: e54.

24. Williams DI, Kenawi MM. The prognosis of pelvi-ureteric obstruction in childhood: A review of 190 cases. Eur J Urol 1976; 2:57–63.

25. Bauer SB, Retik AB. Bladder diverticula in infants and children. J Urol 1974; 3:712–5.

26. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 2002; 113 Suppl 1A:55-13S.

27. Mehmet D et al. URINARY AND SERUM CYTOKINE LEVELS IN PATIENTS UNDERGOING SWL. September - October, 2001;27 (5): 495-499.

28. Lotz M et al. Interleukin-6 and interstitial cystitis. J Urol, 1994;152: 869-873.

29. Hang L et al. Cytokine repertoire of epithelial cells lining the human urinary tract. J Urol.1998; 159: 2185-2192.
30. Ohta K et al. Detection and clinical usefulness of urinary interleukin-6 in the disease of the kidney and the urinary tract. ClinNephrol. 1992; 38: 185-189.

31. Wang J et al. Clinical significance of urinary interleukin-6 in children with reflux nephropathy. J Urol 2001; 165(1):210-214.

32. Sheu JN et al. Serum and urine levels of interleukin-6 and interleukin-8 in children with acute pyelonephritis. Cytokine. 2006; 36:276-82.

33. Krzemien G et al. Urinary levels of interleukin-6 and interleukin-8 in children with urinary tract infections to age 2. Med Sci Monit. 2004;10:CR593-7.

34. Galanakis E et al. Urine interleukin-8 as a Marker of Vesicoureteral Reflux in Infants. Pediatrics 2006;117(5): e863-e867.

35. Chaly Y et al. Differential action of human defensin HNP-1 on production of TNF-a, ILLb and IL-8 by human monocytes in vitro. Cytokine 1995; 7: 629 (A-207)

36. Tullus K et al. Urine interleukin-6 and interleukin-8 in children with acute pyelonephritis, in relation to DMSA scintigraphy in the acute phase and at 1-year follow-up. PediatrRadiol 1994; 24(7):513-515.

37. Tramma D. Interleukin-6 and interleukin-8 levels in the urine of children with renal scarring. PediatrNephrol 2012; 27:1525-1530.

38. Tracey KJ et al. Shock and tissue injury induced by recombinant human cachectin. Science. 1986; 234: 470-474.

39. Ninan GK et al. Urinary cytokines as markers of reflux nephropathy J Urol,1999; 162: 1739-1742.

40. Nakazato Y et al. Interleukin-4 modulates collagen synthesis by human mesangial cells in a type-specific manner. Am. J. Physiol. 1996;270: F447–F453. [PubMed]

41. Sinuani I et al. Role of IL-10 in the progression of kidney disease World J Transplant. 2013 Dec 24;3(4):91-8

42. M. G.Madsen, “Urinary biomarkers in hydronephrosis,” Danish Medical Journal, vol. 60, no. 2, Article IDB4582, 2013.

43. Buckham TA et al. Evaluation of five interleukin genes for association with end-stage renal disease in white Europeans. Am J Nephrol. 2010, 32: 103-108.

44. Balakrishnan VS et al. Cytokine gene polymorphisms in hemodialysis patients: association with comorbidity, functionality, and serum albumin. Kidney Int. 2004; 65: 1449-1460.

45. Carrero JJ et al. Cytokines, atherogenesis, and hypercatabolism in chronic kidney disease: a dreadful triad. Semin Dial. 2009; 22: 381-386.

46. Silverstein DM: Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease. Pediatr Nephrol. 2009; 24: 1445-1452.